enVVeno Medical (NVNO) EBITDA (2017 - 2026)

enVVeno Medical has reported EBITDA for 10 years, with the latest figure at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 18.01% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$20.0 million (up 14.05% YoY), and the FY2025 full-year result was -$20.9 million, up 12.28% from the prior year.
• EBITDA for Q1 2026 stood at -$4.1 million, down from -$4.0 million in the prior quarter.
• The five-year high for EBITDA was -$4.0 million in Q4 2025, with the low at -$7.0 million in Q2 2025.
• Average EBITDA over 5 years is -$5.8 million, with a median of -$6.2 million recorded in 2022.
• Year-over-year, EBITDA plunged 192.79% in 2022 and soared 40.1% in 2025.
• Tracing NVNO's EBITDA over 5 years: stood at -$6.5 million in 2022, then rose by 2.82% to -$6.3 million in 2023, then dropped by 6.71% to -$6.7 million in 2024, then soared by 40.1% to -$4.0 million in 2025, then declined by 1.22% to -$4.1 million in 2026.
• The last three EBITDA figures came in at -$4.1 million (Q1 2026), -$4.0 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.

Peer Comparison